Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

bausch & lomb australia pty ltd - 15652 - loupe - a convex lens with a built-in electrical light source used for magnifying vision and concentrating the light upon an object or objects being viewed. it can be used for a variety of purposes, eg the examination of an object for laboratory work, minor surgery, dermatology, or by persons with a strong eyesight impairment. the loupe is typically mounted on the end of an adjustable arm (eg, a flexible or an articulating arm) which is attached to a stable base or clamped to a surface worktop.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

siemens healthcare pty ltd -

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

hologic (australia & new zealand) pty ltd -

Awstralja - Ingliż - APVMA (Australian Pesticides and Veterinary Medicines Authority)

bayer cropscience pty ltd - phenmedipham - suspoemulsion - phenmedipham carbamate-phenylcarbamate active 160.0 g/l - herbicide - beetroot | silver beet | mangold | spinach beet | sugar or fodder - barley grass | bellvine | bindweed | blackberry nightshade | charlock | chickweed | cleavers | common fumitory | common groundsel | common pigweed | common thornapple | corn spurry | deadnettle | fat hen | green amaranth | lesser swinecress or bittercress | penny cress | persicaria | potato or yellow weed | prairie grass | redshank,slim or spleen amaranth | shepherd's purse | sow or milk thistle | stinging or dwarf nettle | summer grass | wild radish or radish weed | winter grass | wireweed, knotweed or hogweed | yellow alkanna or alkanet | alkanna lutea | amaranthus cruentus | annual blue grass | annual dwarf nettle | annual nettle | annual poa | bastard cress | black nightshade | brassica kaber | brassica sinapistrum | common chickweed | common sowthistle | cornbine (uk) | devil's thornapple | dwarf nettle | english stinging nettle | european bindweed | fallopia aviculare | fallopia persicaria | false castor oil | field bindweed | field morning glory (usa) | fumitory | galinsoga | goose grass | groundsel |

Awstralja - Ingliż - APVMA (Australian Pesticides and Veterinary Medicines Authority)

elanco australasia pty ltd - cloprostenol as the sodium salt - parenteral liquid/solution/suspension - cloprostenol as the sodium salt prostaglandin active 250.0 ug/ml - endocrine system - cow | horse mare (female) | bovine | female cattle | female horse - control of oestrus | cystic ovaries | early foetal death | extended dioestrus | induce abortion | induction of parturition | lactation anoestrus | pseudo-pregnancy | pyometra | sub oestrus | synchronisation of oestrus | induction of calving | prolonged weaning to mating | pseudo-cyesis | pseudo-pregnancy lactation | silent heat

Iżrael - Ingliż - Ministry of Health

neopharm scientific ltd - a/california/7/2009 (h1n1)pdm09-like virus; a/hong kong/4801/2014 (h3n2) - like virus; b/brisbane/60/2008 - like virus - suspension for injection - b/brisbane/60/2008 - like virus 15 mcg / 0.5 ml; a/hong kong/4801/2014 (h3n2) - like virus 15 mcg / 0.5 ml; a/california/7/2009 (h1n1)pdm09-like virus 15 mcg / 0.5 ml - vaccinia immunoglobulin - vaccinia immunoglobulin - active immunisation against influenza in the elderly (65 years of age and over), especially for those with an infreased risk of associated complications (i.e. patients affected by underlying chronic diseases including diabetes, cardiovascular and respiratory diseases).

Iżrael - Ingliż - Ministry of Health

j-c health care ltd - abiraterone acetate - tablets - abiraterone acetate 250 mg - abiraterone - abiraterone - zytiga is a cyp17 inhibitor indicated:- in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer.- for the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt).

Iżrael - Ingliż - Ministry of Health

pfizer pharmaceuticals israel ltd - etanercept - powder and solvent for solution for injection - etanercept 25 mg/vial - etanercept - etanercept - rheumatoid arthritis:- enbrel is indicated for the treatment of active rhematoid arthritis in adults when the response to disease-modifying antirheumatic drugs (dmards) including methotrexate (unless contraindicated) has been inadequate. enbrel can be used in combination with methotrexate in patients who do not respond adequately to methotrexate alone. - reducing signs and symptoms and inhibiting the progression of structural damage in patients with moderately to severely active rheumatoid arthritis.enbrel, alone or in combination with methotrexate, has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function.* psoriatic arthritistreatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying antirheumatic drug therapy has been inadequate. enbrel has been shown to improve physical function in patients with psoriatic arthritis, and to reduce the rate of progression of peripheral joint damage as measured by x ray in patients with polyarticular symmetrical subtypes of the disease. * plaque psoriasis treatment of adults patients (18 years or older) with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.* paediatric plaque psoriasis treatment of chronic severe plaque psoriasis in children and adolescents from the age of 6 years who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies.* juvenile idiopathic arthritis- treatment of polyarthritis (rheumatoid factor positive or negative) and extended oligoarthritis in children and adolescents from the age of 2 years who have had an inadequate response to, or who have proved intolerant of, methotrexate. - treatment of psoriatic arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, methotrexate.- treatment of enthesitis-related arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, conventional therapy.*axial spondyloarthritis- ankylosing spondylitis(as)treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy.- non-radiographic axial spondyloarthritistreatment of adults with severe non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) evidence, who have had an inadequate response to nonsteroidal anti-inflammatory drugs (nsaids).

Iżrael - Ingliż - Ministry of Health

pfizer pharmaceuticals israel ltd - etanercept - solution for injection - etanercept 50 mg/ml - etanercept - etanercept - * rheumatoid arthritis:- enbrel is indicated for the treatment of active rhematoid arthritis in adults when the response to disease-modifying antirheumatic drugs (dmards) including methotrexate (unless contraindicated) has been inadequate.. enbrel can be used in combination with methotrexate in patients who do not respond adequately to methotrexate alone. - reducing signs and symptoms and inhibiting the progression of structural damage in patients with moderately to severely active rheumatoid arthritis.enbrel, alone or in combination with methotrexate, has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function.* psoriatic arthritistreatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying antirheumatic drug therapy has been inadequate. enbrel has been shown to improve physical function in patients with psoriatic arthritis, and to reduce the rate of progression of peripheral joint damage as measured by x ray in patients with polyarticular symmetrical subtypes of the disease. * plaque psoriasis treatment of adults patients (18 years or older) with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.* paediatric plaque psoriasis treatment of chronic severe plaque psoriasis in children and adolescents from the age of 6 years who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies.* juvenile idiopathic arthritis- treatment of polyarthritis (rheumatoid factor positive or negative) and extended oligoarthritis in children and adolescents from the age of 2 years who have had an inadequate response to, or who have proved intolerant of, methotrexate. - treatment of psoriatic arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, methotrexate.treatment of enthesitis-related arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, conventional therapy. enbrel has not been studied in children aged less than 2 years.* axial spondyloarthritis- ankylosing spondylitis(as)treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy.- non-radiographic axial spondyloarthritistreatment of adults with severe non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) evidence, who have had an inadequate response to nonsteroidal anti-inflammatory drugs (nsaids)

Iżrael - Ingliż - Ministry of Health

pfizer pharmaceuticals israel ltd - etanercept - solution for injection - etanercept 50 mg/ml - etanercept - etanercept - * rheumatoid arthritis:- enbrel is indicated for the treatment of active rhematoid arthritis in adults when the response to disease-modifying antirheumatic drugs (dmards) including methotrexate (unless contraindicated) has been inadequate.. enbrel can be used in combination with methotrexate in patients who do not respond adequately to methotrexate alone. - reducing signs and symptoms and inhibiting the progression of structural damage in patients with moderately to severely active rheumatoid arthritis.enbrel, alone or in combination with methotrexate, has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function.* psoriatic arthritistreatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying antirheumatic drug therapy has been inadequate. enbrel has been shown to improve physical function in patients with psoriatic arthritis, and to reduce the rate of progression of peripheral joint damage as measured by x ray in patients with polyarticular symmetrical subtypes of the disease. * plaque psoriasis treatment of adults patients (18 years or older) with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.* paediatric plaque psoriasis treatment of chronic severe plaque psoriasis in children and adolescents from the age of 6 years who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies.* juvenile idiopathic arthritis- treatment of polyarthritis (rheumatoid factor positive or negative) and extended oligoarthritis in children and adolescents from the age of 2 years who have had an inadequate response to, or who have proved intolerant of, methotrexate. - treatment of psoriatic arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, methotrexate.treatment of enthesitis-related arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, conventional therapy.enbrel has not been studied in children aged less than 2 years.* axial spondyloarthritis- ankylosing spondylitis(as)treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy.- non-radiographic axial spondyloarthritistreatment of adults with severe non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) evidence, who have had an inadequate response to nonsteroidal anti-inflammatory drugs (nsaids).